2013 Rieveschl Award for Distinguished Scientific Research: George Deepe, MD
UC is known for excellence in research, and George Deepe, MD, has played a part in that reputation with his contributions to infectious diseases research.
For over 30 years as a faculty member at UC, Deepe, who also served for 15 years as chief of the division of infectious diseases, has been a leading researcher and a world-recognized expert in the study of Histoplasma capsulatum, a pathogenic fungus that causes infection, particularly in the Ohio River Valley.
For his work, he has been selected as UCs 2013 recipient of the George Rieveschl Jr. Award for Distinguished Scientific Research. He was honored at the All-University Faculty Awards celebration April 17, 2013.
Deepe has consistently received federal and private funding for his research and has been awarded a number of honors, including the Research Career Development Award from the National Institute of Allergy and Infectious Diseases (NIAID) from 1987 to 1992 and the MERIT Award from the NIAID from 1997 to 2007.
In addition to his outstanding research portfolio, Deepe is heavily involved in mentoring graduate students and currently serves as associate director of the UC Medical Scientist Training Program.
He excels in research, education and clinical care but is known among his colleagues and mentees as being a fun, intelligent and caring personsomeone you can always come to with a problem.
One of his nominators wrote: "George is well known in our academic community for his great sense of humor, deep literary background, unstinting loyalty and enormous generosity of spirit.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.